Identification of interleukin-6 trans-signalling as a novel target for therapeutic approaches to lung cancer [ 2014 - 2016 ]

Research Grant

Researchers: Prof Brendan Jenkins (Principal investigator) ,  Prof Stefan Rose-John

Brief description Interleukin-6 (IL-6) has been implicated as a causative factor in lung cancer, the most lethal cancer worldwide, albeit by unknown mechanisms. Since IL-6 is also important for immune system homeostasis, the development of anti-IL-6 therapies requires an intimate knowledge of pathological versus physiological IL-6 signalling pathways. This project aims for the first time to define an alternative IL-6 signalling pathway, termed “trans signalling”, in the molecular pathogenesis of lung cancer.

Funding Amount $AUD 627,089.27

Funding Scheme Project Grants

Notes Standard Project Grant